Filing identity and reporting period
Important issuer mismatch: The request identifies Processa Pharmaceuticals, Inc., but the supplied Form 10-K is for Heatwurx, Inc. This summary reflects Heatwurx’s fiscal year ended December 31, 2016 and should not be attributed to Processa Pharmaceuticals.
Heatwurx developed asphalt-repair equipment and technology. By 2016 it had sharply reduced operations, discontinued its Dr. Pave businesses, and retained minimal activity to support one licensee and seek a merger candidate. It reported no contracted revenue or immediate sales prospects.
Financial performance and condition
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $5,000 | $113,425 |
| Gross profit (loss) | $5,000 | ($12,451) |
| Loss from continuing operations | ($337,179) | ($2,982,920) |
| Net loss | ($335,982) | ($3,354,227) |
| Net loss per common share | ($0.03) | ($0.31) |
| Cash used in operating activities | ($43,203) | ($871,906) |
SG&A fell to approximately $70,000 from $945,000, principally due to reduced staffing and overhead. The smaller net loss also reflects 2015 impairment charges of approximately $1.52 million for intangible assets and $186,000 for assets held for sale. Revenue declined about 96%; management said it did not anticipate equipment-sale revenue in 2017.
At year-end, cash was $3,237, total assets were $3,237, current liabilities were $2.35 million, and stockholders’ deficit was $2.35 million. The filing reports $1.61 million in principal obligations: $962,361 in senior secured notes, $420,000 in unsecured notes, and a $229,980 revolving line of credit. Accrued interest was also substantial; the filing separately cites $2.05 million of continuing-operations debt and accrued interest. All listed principal obligations were past due or in default. The company reported no cash interest payments in 2016.
Changes, outlook, and key risks
- Financing from the small group of existing investors had largely stopped; only $15,000 was raised under the senior secured loan in 2016. Management said it could not obtain adequate alternative financing or generate sufficient revenue to support its cost structure.
- The senior secured notes bear 12% interest, with overdue interest subject to an 18% rate under specified terms, and are secured by all company assets, including intellectual property. Creditors could foreclose. The revolving credit line was also in default.
- Management stated that the conditions raise substantial doubt about the company’s ability to continue as a going concern. Its plan was to seek a merger or acquisition; absent a candidate, it would cease operations.
- After year-end, the company disclosed additional secured borrowing of $195,000 in June–August 2017 and a non-binding letter of intent for a reverse merger with Promet Therapeutics, LLC. The filing does not report a completed transaction.
- The independent auditor issued an unmodified opinion on the financial statements but highlighted substantial doubt about going concern. Management reported ineffective disclosure controls and internal financial controls, citing inadequate accounting resources; the weakness had not been remediated.
- Other risks include reliance on one customer for all 2016 revenue, related-party debt and potential conflicts, limited staffing, possible dilution from outstanding warrants and options, and illiquid OTC trading. The filing says the company had 11,017,388 common shares outstanding at year-end and 2,000,304 warrants outstanding.
Important facts for investors to verify
- Confirm that Heatwurx—not Processa Pharmaceuticals—is the intended issuer and that this 2016 annual report is the intended filing.
- Verify the current status, maturity, accrued interest, default remedies, and creditor actions for each debt facility, including the discrepancy between principal obligations and the larger debt-and-accrued-interest figure.
- Check whether the Promet reverse-merger letter of intent proceeded, and review subsequent filings for financing, merger, or cessation-of-operations developments.
- Assess the company’s cash runway, current liabilities, control weaknesses, and ability to continue reporting; the report states it was delinquent in Exchange Act filings for 2016.
- Review the terms and potential dilution from warrants, options, and preferred stock, as well as related-party lender relationships.